Author

Subrata Ghosh

Exploring the evolution of care in Crohn’s disease (Janssen)
Exploring the evolution of care in Crohn’s disease (Janssen)

Subrata Ghosh  et al.

Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)
Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)

Subrata Ghosh  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS
SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Subrata Ghosh  et al.

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS
SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Subrata Ghosh  et al.

Walk this way: navigating the evolving UC treatment pathway (Galapagos)
Walk this way: navigating the evolving UC treatment pathway (Galapagos)

Subrata Ghosh  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Subrata Ghosh  et al.

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION
LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

Subrata Ghosh  et al.

DELAYED IBD DIAGNOSIS LEADS TO WORSE OUTCOMES OVER YEARS, WITH MULTIPLE IMPLICATIONS ON SERVICE DELIVERY
DELAYED IBD DIAGNOSIS LEADS TO WORSE OUTCOMES OVER YEARS, WITH MULTIPLE IMPLICATIONS ON SERVICE DELIVERY

Subrata Ghosh  et al.

DELAYED IBD DIAGNOSIS INCREASES RISK OF REQUIRING BIOLOGICS IN FIRST 4-YEARS - AN INCEPTION COHORT STUDY
DELAYED IBD DIAGNOSIS INCREASES RISK OF REQUIRING BIOLOGICS IN FIRST 4-YEARS - AN INCEPTION COHORT STUDY

Subrata Ghosh  et al.

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Subrata Ghosh  et al.

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Subrata Ghosh  et al.

USTEKINUMAB THERAPY AFTER BIOLOGIC FAILURE IN PATIENTS WITH CROHN’S DISEASE – A REAL-WORLD SINGLE CENTRE EXPERIENCE
USTEKINUMAB THERAPY AFTER BIOLOGIC FAILURE IN PATIENTS WITH CROHN’S DISEASE – A REAL-WORLD SINGLE CENTRE EXPERIENCE

Subrata Ghosh  et al.

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Subrata Ghosh  et al.

RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Subrata Ghosh  et al.

EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Subrata Ghosh  et al.

RESPONSE TO BIOLOGICS IN IBD PATIENTS ASSESSED BY COMPUTERIZED IMAGE ANALYSIS OF PROBE BASED CONFOCAL LASER ENDOMICROSCOPY WITH MOLECULAR LABELING
RESPONSE TO BIOLOGICS IN IBD PATIENTS ASSESSED BY COMPUTERIZED IMAGE ANALYSIS OF PROBE BASED CONFOCAL LASER ENDOMICROSCOPY WITH MOLECULAR LABELING

Subrata Ghosh  et al.

Item 1 - 20 / 28
1
2